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Abstract
Several haloperidol derivatives with a piperidine scaffold that was decorated at the nitrogen atom with different alkyl,
benzyl, or substituted benzyl moieties were synthesized at our laboratory to establish a library of compounds with
vasodilator activity. Compounds were screened for vasodilatory activity on isolated thoracic aorta rings from rats, and their
quantitative structure–activity relationships (QSAR) were examined. Based on the result of QSAR, N-4-tert-butyl benzyl
haloperidol chloride (16c) was synthesized and showed the most potent vasodilatory activity of all designed compounds.
16c dose-dependently inhibited the contraction caused by the influx of extracellular Ca
2+ in isolated thoracic aorta rings
from rats. It concentration-dependently attenuated the calcium channel current and extracellular Ca
2+ influx, without
affecting the intracellular Ca
2+ mobilization, in vascular smooth muscle cells from rats. 16c, possessing the N-4-tert-butyl
benzyl piperidine structure, as a novel calcium antagonist, may be effective as a calcium channel blocker in cardiovascular
disease.
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Introduction
Calcium is essential for life and is the most common signal
transduction element in cells [1,2]. The contraction of all types of
muscle primarily depends on increased intracellular Ca
2+ [3].
Calcium channel blockers constitute an important class of cardio-
vascular drugs. Members of this class are clinically useful in the
treatment of cardiovascular disorders in which calcium plays a
regulatory role. However, most cannot be used to resolve clinical
problems such as ischemia, reperfusion injury, and vascular structure
remodeling [4]. Furthermore, some of them have serious side effects.
Therefore, better calcium channel blockers are still needed.
Haloperidol is a widely used antipsychotic whose therapeutic
properties have been associated with its D2 antagonist activity on
the basis of the so-called dopamine hypothesis [5]. N-Benzyl
haloperidol chloride (4) (Figure 1A), a derivative of haloperidol,
was synthesized at our laboratory and was found to have a
vasodilator effect [6]. Our previous study revealed that 4’s
inhibitory effect on the influx of extracellular Ca
2+ might be
related to vasodilatory mechanisms [7]. Furthermore, the N-benzyl
piperidine structure of 4 is completely different from that of the
clinically used calcium channel blockers, which belong to one of
the following three chemical classes: the dihydropyridines, the
phenylalkylamines, and the benzothiazepines [8]. Therefore, a
novel calcium channel antagonist may be obtained by molecular
manipulation of the structure of 4, which itself is not a sufficiently
potent vasodilator.
With the aim of exploring the structure–activity relationship
of 4 and obtaining more efficient calcium channel blockers, we
had cultured single crystals to determine the structure of 4.
Furthermore we designed the series of compounds shown in Table
S1. In addition, we revealed some haloperidol derivatives
(compounds 6a–6c, 9a–9c in Table S1) had vasodilator activity
in previous study [9]. The piperidine scaffold, which we consider a
supporting structure for novel calcium channel antagonists, was
decorated at the nitrogen atom of piperidine with different
substituent groups. We screened these compounds for vasodilatory
activity in isolated rat thoracic aorta rings held in a Ca
2+-
containing high-K
+ solution. A detailed quantitative structure–
activity relationship (QSAR) analysis of this series of haloperidol
derivatives was subsequently performed to study the physicochem-
ical properties that were responsible for their activity. Base on the
result of QSAR, we synthesized N-4-tert-butyl benzyl haloperidol
chloride (16c) which was found to posses a good vasodilative
activity in KCl-constricted vessels in line with expectation.
Many studies have demonstrated that vasorelaxation in KCl-
constricted vessels can be ascribed directly to the inactivation of
voltage-dependent Ca
2+ channels (VDCCs) [10]. Hence, 16c was
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caused by an influx of exogenous Ca
2+ in thoracic aorta rings to
prove that its vasodilator activity was related to Ca
2+. Then,
the inhibitory effects of 16c on the activity of VDCCs, the
extracellular Ca
2+ influx, and the intracellular Ca
2+ release in
vascular smooth muscle cells (VSMCs) were explored in detail to
reveal the calcium antagonist mechanism.
Results
Synthesis
The reaction pathways used to synthesize the designed
compounds (compounds 1–16) were described in Schemes S1,
S2, and the chemical and physical characteristics of the
compounds were reported in Table S1. The key intermediate
haloperidol (4-[4-(4-chlorophenyl)-4-hydroxy-1- piperidyl]-1-
(4-fluorophenyl)-butan-1-one) could be obtained via piperidyl
alkylation reaction according to the literature [11]. Commercially
available alkyl and benzyl halides were used. Some of benzyl
halides (compounds I–V) were synthesized from the corresponding
benzaldehyde compounds (Scheme S1). The quaternary ammo-
nium salt derivatives of haloperidol (compounds 1–16) were
synthesized from haloperidol by alkylation or benzylation at the
nitrogen atom using a suitable alkyl or benzyl halide (Scheme S2).
In order to know about the structure of 4 as the leading compound
clearly, we had cultured single crystals and determined the crystal
structure by X-ray single crystal diffraction (Figure 1B, Table S2).
The chemical structures of these compounds were characterized
by
1H NMR spectra (Table S3). 16c was illustrated as a
representation in Figure 2.
Determination of vasorelaxation
All synthesized compounds caused a concentration-dependent
relaxation of aortic rings that had been precontracted to varying
extents with a high level of K
+ (80 mM). The vehicle (0.1%
DMSO) used for all compounds had no effect on vascular tone.
Concentration–response curves were determined for each com-
pound, and the potency was expressed as the IC50 value in the
presence and absence of endothelium (Table S4). From Table S4,
we can see no significant IC50 difference between aortic rings with
intact endothelium or denuded endothelium. Concentration-
response curves showed no significant shift in the absence of
endothelium, than in the presence of endothelium, which
suggested no nitric oxide involvement in the vasodilatation (data
not shown).
QSAR study of some derivatives. A detailed QSAR
analysis of a series of haloperidol derivatives (compounds 4–15,
splitting into a testing set of 3 compounds which are randomly
selected and training set of 26 compounds) had been performed to
determine the physicochemical properties responsible for their
activity. The physicochemical parameters used were listed in
Table 1, namely the hydrophobic constant p, Hammett s, molar
refractivity (MR), and were compiled from the literature [12–14].
The IC50 values were transformed to pIC50 (negative logarithm of
IC50). The QSAR results indicated that activity was best modeled
by molecular steric parameters represented by MR, hydrophobic
parameters represented by p. The best QSAR obtained was:
pIC50~0:238MRpz0:181 p- 0:195 MRoz5:061
The subscripts in the parameter relate to the position of the
substituent considered. A determinants of coefficient R
2 is 0.787
for 26 compounds in training set, and the residuals of compounds
9b,11b,14c as testing set are 0.03176; 0.1224, 0.00163. It
confirmed that the equation was of some value in predicting
activity (Table 1, Figure 3).
The inhibitory action of 16c on the contraction caused by
KCl and the influx of extracellular Ca
2+
The results indicated 16c showed the most significant
vasorelaxation effect on KCl-dependent contraction compared
with compounds 1–15, and the IC50 value of 16c was 0.95 mM
(Table 1). And 16c was chosen for further research.
KCl-dependent contraction is due to the influx of extracellular
Ca
2+ through VDCCs [10]. We first investigated the ability of 16c
to inhibit the contraction induced by the exogenous application
of Ca
2+ in a Ca
2+-free high-K
+ solution. As Figure 4 showed, 16c
at different concentrations (0.1—10 mM) significantly impaired
the response to Ca
2+ (3 mM) to 87.49%—11.02% of the initial
response. The IC50 value was 0.76 mM, similar to the result
obtained from the determination of vasorelaxation (Table S1,
Table 1). The results indicated that 16c inhibited the responses to
Ca
2+ in a concentration-dependent manner. So we deduced that
16c significantly inhibited the response to Ca
2+ influx from the
extracellular space.
Effects of 16c on [Ca
2+]i in arterial VSMCs. The Ca
2+
responses of arterial VSMCs to KCl (80 mM) were studied after
incubation with 16c. 16c did not affect basal [Ca
2+]i (29.861.2 vs
30.761.4 nM for 16c and control, respectively, n=25, p.0.05).
The response of the control cells to KCl was characterized by a
sharp increase in [Ca
2+]i (from 30.1862.82 to 103.3467.26 nM,
mean 6S.E. n=24) followed by a sustained plateau (106.646
6.24 nM at 200 s). This response was totally inhibited by 16c at 0.1,
1, 10 mM( b o t hK C l
peak and KCl
200 s=89.7664.96, 57.2463.64,
42.3262.65 nM, respectively n=24, p,0.01 vs control values;
Figure 5).
Effect of 16c on L-type Ca
2+ channel activity. We then
applied the patch-clamp technique to measure the effect of 16c on
the activity of VDCCs on the primary cells. In our study, IBa was
elicited by depolarization from the depolarizing potential of
230 mV to +50 mV. The peak IBa was elicited at the potential
of 0 mV. Barium currents were reversibly inhibited by 1 mM
nimodipine, and augmented by 50 nM Bay K 8644 (data not
shown). 16c (10, 1, 0.1 mM) reduced the peak current to
21.365.1% (p,0.01, n=5), 39.466.2% (p,0.01, n=5),
89.8615.1% (p,0.01, n=5) of control values, respectively
(Figure 6A). The VSMCs showed current/voltage relationships
typical of high voltage-activated L-type Ca
2+ channels, with
apparent threshold and reversal potentials of approximately 230
and +50 mV, respectively (Figure 6B). No change in leak current
Figure 1. The chemical structure of 4(A), The molecular
structure of 4 (B).
doi:10.1371/journal.pone.0027673.g001
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suggests that at these concentrations, the compounds had no
‘‘detergent-like’’ effect on cell plasma membrane. Half-maximal
inhibition of the Ca
2+ channel current was observed at about
1 mM.
Discussion
Calcium channel blockers play an important role in cardiovas-
cular diseases, but better drugs are still needed for some clinical
problem. In our study, we found some Haloperidol derivatives
showed vasorelaxation activity to varying degree. We synthesized a
series of haloperidol derivatives and we used the test of vasodilator
effect on the rat isolated thoracic aorta rings with a high level of
K
+ (80 mM) to screen molecules for further studies, and examined
the structure-activity relationship of compounds. Studies have
demonstrated that the contraction of vascular smooth muscle is
initiated by an increased intracellular calcium level [15–17], which
may be achieved in two ways: extracellular Ca
2+ influx from
VDCCs evoked by depolarization with high potassium concen-
tration, and intracellular Ca
2+ release from the intracellular stores
[18,19]. From the result, we can deduce these compounds’
inhibition on the contraction of the vascular smooth muscle might
relate to the extracellular Ca
2+ influx from VDCCs evoked by
depolarization with high K
+.
Furthermore, most published QSARs show the importance of
particular physicochemical parameters in describing activity [20].
We observed a correlation between the pharmacological activities
and structures in this study. The best QSAR obtained was:
pIC50=0.238 MRp+0.181 p- 0.195 MRo+5.061. This result
showed that the main factors governing activity were the MR
term of the specific position of the substituent which will determine
the fit at the receptor site and the hydrophobic parameters which
determine the ability of the compounds to transport the cellular
Figure 2. The chemical structure of 16c (A); 400 MHz
1H NMR spectrum of 16c in CDCl3 (B); Infrared Spectroscopy of 16c (C).
doi:10.1371/journal.pone.0027673.g002
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the cellular membrane. In addition, compound 4 displayed higher
vasodilation activity than compounds 1–3 (from Table S1). These
results also indicated that for this series of derivatives, the MR
term of a particular molecule was the significant element of the
substituent. The importance of both the substituent steric
parameters and their position appears to be in their ability to
maintain the molecule in an orientation that is conducive to
receptor binding. This was inferred from the fact that MR term, as
a steric parameter was consistently expressed in a regression
analysis. The equation also highlighted the importance of the
substituent for vasodilator activity in the ortho- and para-positions.
The MR parameter needs some discussion at this point. MR has
been viewed as a measure of bulk and as a ‘‘rough and ready’’
steric parameter. It is used to model the intermolecular effects
between a ligand and receptor. From the x-ray structure of 4
(Figure 1B), it is easy to understand that the negative ortho effect
may be due to a conformational preference of 4-phenyl piperidine
ring for the substituted benzyl group. It is, therefore, most
probably due to direct steric hindrance interfering with drug
receptor binding [21]. Although a more complex problem
involving, interpretation of a positive coefficient with MR revealed
that the steric effect at the para-position of the aryl ring was
advantageous to the activity. In summary, the result showed
activity may be further improved if substituents with greater
hydrophobic parameters in the para-position are considered (such
as p-C (CH3)3, p-(CH2)4N(CH3)3
+, p-(CH2)4C6H5). The com-
pound with p-(CH3)3 had a lower molecular weight than the others
(such as p-(CH2)4N(CH3)3
+, p-(CH2)4C6H5). So this compound
(16c) was designed and synthesized, and 16c showed the most
potent vasorelaxation effect agreeing with the predicted effect
(experimental IC50: 0.95 mM, predicted IC50: 1.36 mM, Table 1).
As KCl-dependent contraction is due to the influx of extracellular
Ca
2+ through VDCCs [10], it is likely that the haloperidol derivatives,
such as 16c, may have effects on the inhibition of the influx
extracellular Ca
2+, and the blockade of calcium channels. The ability









4 0 0 0.1 0.1 0.1 24.9965 25.06832
5a 20.67 20.2 0.28 0.1 0.1 24.8877 24.91286
5b 20.67 0.12 0.1 0.28 0.1 24.9597 24.94857
5c 20.67 20.37 0.1 0.1 0.28 24.9974 24.99122
6a 0.71 0.40 0.6 0.1 0.1 25.07 25.09602
6b 0.71 0.37 0.1 0.6 0.1 25.2097 25.19522
6c 0.71 0.23 0 0.1 0.6 25.3001 25.33352
7b 0.64 0.39 0.1 1.25 0.1 25.0074 25.18271
7c 0.64 0.31 0.1 0.1 1.25 25.2111 25.45515
8a 0.88 0.97 0.5 0.1 0.1 25.0301 25.14624
8b 0.88 0.64 0.1 0.5 0.1 25.3595 25.22561
8c 0.88 0.56 0.1 0.1 0.5 25.44 25.32037
9a 0.56 0.93 0.56 0.1 0.1 25.07 25.07715
9b
& 0.56 0.8 0.1 0.56 0.1 25.1999 25.16814
9c 0.56 0.73 0.1 0.1 0.56 25.27 25.27739
10a 0.14 0.98 0.09 0.1 0.1 25.02 25.09533
10b 0.14 0.92 0.1 0.09 0.1 25.0798 25.09335
10c 0.14 0.93 0.1 0.1 0.09 25.07 25.09098
11a 20.28 1.03 0.74 0.1 0.1 24.9698 24.8913
11b
& 20.28 0.86 0.1 0.74 0.1 25.1402 25.01778
11c 20.28 0.73 0.1 0.1 0.74 25.27 25.1699
12c 1.53 20.15 0.1 0.1 1.50 25.6458 25.67345
13b 20.01 0.36 0.1 1.29 0.1 25.266 25.06654
13c 20.01 0.45 0.1 0.1 1.29 25.4485 25.34845
14a 20.57 1.28 0.63 0.1 0.1 24.7201 24.86129
14b 20.57 1.07 0.1 0.63 0.1 24.9299 24.96587
14c
& 20.57 0.91 0.1 0.1 0.63 25.0899 25.08827
15a 1.02 20.17 1.03 0.1 0.1 25.1598 25.06611
15c 1.02 20.15 0.1 0.1 1.03 25.58 25.47095
16c 1.98 20.02 0.1 0.1 1.96 26.0222 25.86636
*, IC50: The half maximal inhibitory concentration,
#,M R o: molar refractivity in ortho-position, MRm: molar refractivity in meta-position, MRp: molar refractivity in para-position.
&, compounds as testing set and their predicted IC50 were calculated by QSARs model.
doi:10.1371/journal.pone.0027673.t001
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of Ca
2+ then was confirmed in a Ca
2+-free high-K
+ solution. This




2+]i level is the main trigger for VSMC
contraction [22], and we showed that 16c had an inhibitory effect
on the contraction induced by exogenous Ca
2+. To reveal the
molecular mechanism by which 16c inhibited vasoconstriction and
to obtain more information about the effect of 16c on calcium
ions, we studied the effect of 16c on Ca
2+ signaling in VSMC
by LSCM. The increase in [Ca
2+]i is believed to result from
Ca
2+ influx, corresponding to the opening of the voltage-sensitive
plasma membrane Ca
2+ channels [23]. This response was
inhibited by 16c, which is consistent with the results in intact
Figure 3. Correlation between predicted activities (IC50) by QSARs models and the experimental activities (IC50) (for compounds of
training set, R
2=0.787; for randomly selected compounds 9b,11b,14c as testing set, Residue are 0.03176; 0.1224, 0.00163.
Correlation is significant at the 0.01 level.).
doi:10.1371/journal.pone.0027673.g003
Figure 4. Cumulative concentration-response curves for Ca
2+ in the presence of the vehicle and increasing concentrations of 16c
(0.1–10 mM) in isolated endothelium-intact aortic rings (n=5). Results are the mean 6S.E. from 5 independent experiments.
doi:10.1371/journal.pone.0027673.g004
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Ca
2+ signaling indicated that 16c decreased the influx of
extracellular Ca
2+ caused by depolarization in VSMCs.
Based on these findings, we therefore postulate that the
compounds targeted the plasma membrane, especially the VDCCs
present in VSMCs. The patch-clamp technique was applied to
measure the effect of 16c on the activity of VDCCs on the primary
cells. 16c obviously suppressed the calcium channel current and
the I-V relation of IBa indicated that the blocking effect of 16c on
calcium channels was voltage-independent. Studies indicate two
types (L and T) of calcium channel exist in VSMCs [24]. Under
the condition of individual cell depolarization from a holding
potential of 240 mV, the L-type calcium channel was activated,
and the T-type Ca
2+ and Na
+ channels were inactivated.
Moreover, TEA, a non-specific K channel blocker, was admin-
istered in the extracellular solution. The pipette solution was
also filled with 4-AP (a K
+ channel blocker). So the outward K
+
currents were completely blocked [25]. In addition, Barium
currents were reversibly inhibited by 1 mM nimodipine, and
augmented by 50 nM Bay K 8644, an activator of L-type Ca
2+
channels [26] in our study. Therefore, the inward current we
recorded under these conditions was an L-type Ca
2+ current.
Obviously, 16c suppressed the L-type calcium channel current. In
addition, we can infer the mechanism of 16c inhibition of L type
Ca
2+ channels, from the structure of 4-phenyl piperidine which
exists in the haloperidol derivatives. In our study, the structure-
activity relationship analysis indicated the 16c and other
haloperidol derivatives, which contain 4-phenyl piperidine ring
possess calcium channel blocking (CCB) activity and the
conformation of the 4-phenyl piperidine ring correlates with the
CCB activity. The piperidine ring is the hydride 1, 4-DHP ring.
Studies on the structure of nifedipine demonstrated the 1, 4-
dihydropyridine (1, 4-DHP) ring system which was perpendicular
to the C-4 substituted-phenyl ring, was the determinant of calcium
channel antagonist activity [27]. Therefore we suppose the
mechanism of 16c in the block of L-type Ca
2+ channel is probably
Figure 5. Effect of 16c (0.1,10 mM) and the vehicle (0.1% DMSO) on KCl (80 mM)-induced changes of Ca
2+ concentration in
vascular smooth muscle cells. A, representative Ca
2+ concentration response to KCl ; B, dose-dependent inhibitory effect of 16c on the Ca
2+
concentration response to KCl. Results are the means 6 S.E. (n=24). *, p,0.01 compared with normal. **, p,0.01 compared with model (KCl).
doi:10.1371/journal.pone.0027673.g005
Figure 6. Effect of 16c on L-type Ca
2+ channel currents in vascular smooth muscle cells (A) and on I–V relation of Ba
2+ currents in
vascular smooth muscle cells (B). The step protocol of recording was described in methods section.
doi:10.1371/journal.pone.0027673.g006
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Xenopus oocytes, will be performed to explore the exact
mechanism in our future studies.
Ca
2+ is considered to be an intracellular signal implicated in
both vasoconstriction and proliferation [28]. However, it is well
known that some L-type Ca
2+ channel antagonists(verapamil,
diltiazem, and nifedipine)show little inhibitory effect on the
proliferation of vascular smooth cells, which is related to the
development of vascular diseases [29]. While, it was reported that
16c, a novel channel blocker, had anti-proliferation activity [30].
Ca
2+, as a second messenger, stimulates nuclear transcription
factors Egr-1 expression which involves cell proliferation [30].
We previously showed that Egr-1 overexpression induced cell
proliferation by using antisense Egr-1 ODNs, and demonstrated
that 16c attenuated the Ang II-induced extracellular Ca
2+ influx
and inhibited Egr-1 overexpression. In this study, we demonstrat-
ed further that 16c had vasodilatory activity, although the
vasodilator effect of 16c was not more potent than other L-type
Ca
2+ antagonists (nifedipine, 1–10 nM; verapamil, 0.1–1 mM; and
diltiazem, 0.5–1 mM; concentrations for 50% inhibition of
vascular contractions in rat or rabbit aorta) [31].
However, 16c, as a novel channel blocker, had vasodilatory
activity and anti-proliferation activity that provides a basis for
further studies of novel calcium channel blockers on intervention
of vascular remodeling and atherosclerosis [30].
Methods
Chemistry
General methods for preparation of the haloperidol
derivatives. The preparation of the title compounds was very
simple. Haloperidol was dissolved in chloroform and was then
reacted with benzyl halide under reflux conditions, or
halohydrocarbon (iodomethane, ethyliodide, iodopropane) were
used as a solvent and were reacted with haloperidol directly. All
melting points were taken on a Bu ¨chi apparatus and were
uncorrected. IR spectra were recorded with a Nicolet-Impact 410
system as KBr pellets.
1H NMR spectra were recorded on a
Bruker AM-400 spectrometer (400 MHz). The
1H NMR internal
standard used was tetramethylsilane (TMS). Chromatographic
separations were performed on a silica gel column by gravity
chromatography (Kieselgel 40, 0.01–0.04 mm; Merck). Yields are
given after purification, unless otherwise stated. Where analyses
are indicated by symbols, the analytical results are within 61% of
the theoretical values. All spectral and elemental analysis data
(shown in the Supporting Information) were in agreement with the
assigned structures. All compounds were estimated to be .95%
pure according to analytical reversed-phase high performance
liquid chromatography (RP-HPLC) and detection with MS (see
Supporting Information for details) for details. No UV-active
impurities were observed with analytical RP-HPLC and UV
detection at 245 nm. The data for 16c was displayed as
represented in Figure 2.
Synthesis of compounds 1–3. Haloperidol (10 mM) was
dissolved in the corresponding halohydrocarbon (4 ml). The
mixture was heated in an oil bath for 24 h to maintain reflux
and was then cooled to room temperature. The filtered solid was
recrystallized from an ethanol-water mixed solvent to a crystalline
product.
Synthesis of some benzyl halide (compounds I–V). The
corresponding benzaldehyde compounds (100 mM) were dissolved
in methanol (20 ml)(for I–III) or THF (20 ml) (for IV–V). NaBH4
(200 mM) was then added gradually in ice-bath. The mixtures
were elevated to room temperature and stirred for 5 min(for I–III)
or 1 h (for IV–V). Then water (20 ml) was added to end the
reaction and the mixtures were evaporated to dryness. The
products were again dissolved in ethylacetate (40 mL), washed
with water (20 ml) and ethylacetate extractions were concentrated
to dryness. The products of benzyl alcohol derivatives were
obtained in this step. These products were then dissolved in THF
(20 ml without water, contained DMF 1–2 d), SOCl2 (3 ml) was
added gradually in ice-bath. After the mixtures were stirred at 0uC
for 20 min, reactions were terminated and the pH value of the
mixture was adjusted to about 7 with a 1 N NaOH solution. The
oil layers were separated from the mixture with a separatory
funnel and the products (benzyl halide) were obtained by
distillation. The
1HNMR data of compounds I–V were
compared with literature [32,33], and reported in supporting
information (Table S5).
Others benzyl halide were purchased from Alfa Aesar, A Jhnson
Matthey Company and some Chinese Companies. These compounds
have been confirmed with literature data in HNMR.
Synthesis of compounds 4–16. Haloperidol (10 mM) was
dissolved in chloroform (4 mL) and the corresponding benzyl
halide (30 mM) was then added. The mixture was heated to
maintain reflux for 18–24 h, and was then cooled to room
temperature. The white solid was filtered off, and was washed with
chloroform. The crude product was recrystallized in an ethanol–
water mixed solvent to provide a crystalline product.
Pharmacology
Vasoactivity determination. The vasodilation activity of
compounds 1–16 was evaluated in isolated rat thoracic aortic rings
according to the methods of Towart and Polster et al [34,35].
Thoracic aortas were isolated from male Wistar rats weighing
200–250 g. The vessels were cut into ring segments, 2–3 mm
wide, and 5 rings were obtained from each aorta. Rings were then
mounted in standard 10-mL organ baths filled with Krebs
bicarbonate solution ((PSS), containing (in mM): 118.0 NaCl, 4.7
KCl, 1.2 KH2PO4, 1.2 MgSO4.7H2O, 5.0 glucose, 25.0
NaHCO3, and 2.5 CaCl2.7H2O) at 37uC and were gassed with
95% O2–5% CO2. (pH=7.4). The aortic rings were allowed to
equilibrate for 90 min at a testing tension of 1 g, and were then
depolarized by the addition of a solution of KCl to a final
concentration of 80 mM. The preparations were then extensively
washed with PSS, and a second contraction was evoked by K
+
depolarization (80 mM). When the amplitude of the contraction
reached a plateau, cumulative concentrations of the tested
compounds in a vehicle of water and DMSO (1000:1) were
added every 45 min. Development of antagonism occurred so
slowly that doses had to be increased at established times, without
waiting for complete equilibrium to be reached. Cumulative
concentration-response cures to all compounds were determined
in the absence and presence of endothelium. According to
experimental protocol, when required, the endothelium was
mechanically removed from some rings by gently rubbing the
lumen with the tips of a forceps. Acetylcholine was used to confirm
that the endothelium had effectively been removed from the aortic
rings [36].
Inhibitory action of active compound (16c) on the
contraction caused by influx of extracellular Ca
2+. To
determine the effect of 16c on the response to the influx of
extracellular Ca
2+, the contractile response to the exogenous
application of Ca
2+ was examined in the presence of 16c in Ca
2+-
free high-K
+ solution (80 mM, K
+-HBSS) as previously described
[37]. Aortic rings were initially equilibrated at a resting tension of
1 g in normal Ca
2+-free HBSS for 60 min. The bath medium
was then replaced with Ca
2+-free high-K
+ HBSS for 30 min to
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2+ (3 mM) and this was
considered to be 100% contraction. After a 30 min equilibration
with Ca
2+-free HBSS, the cumulative contractile response to Ca
2+
(0.01–3 mM) was determined in K
+-HBSS in the presence of
increasing concentrations (0.1–10 mM) of 16c. The aortic rings
were incubated with 16c for 10 min before examining the
responses to Ca
2+.
Electrophysiology. Inward barium (IBa) currents were
studied in single cells by the patch-clamp technique in the
perforated-attached configuration [38]. The recordings were made
using a Biologic RK-300 amplifier, filtered (23 dB, 5-pole
Tchebicheff filter) at 1 kHz and sampled at 5 kHz. Currents
were recorded from holding potential 240 mV during linear
voltage ramps from 240 to +60 mV, with 10 mV increments. The
bath solution contained (in mM) NaCl 125, BaCl2 10.8, MgCl2 1,
CsCl 5.4, glucose 10, and Hepes 10 (pH=7.4 at 24uC). Patch
pipettes were pulled from glass capillaries (Warner Instruments)
and were coated with wax to minimize capacitative transients and
noise; the electrode resistance ranged from 2–5 MVwhen filled
with the pipette solution. The patch pipette was filled with a
solution containing (in mM) CsOH 75, CsCl 55, MgCl2 5, aspartic
acid 75, Hepes 10 (pH=7.4 at 22uC). Nystatin (Biochrom KG,
Berlin, Germany) was dissolved in Me2SO and diluted into the
pipette solution to give a final concentration ranging from 50 to
100 mg/mL. Drugs were applied by changing the bath solution.
The final concentration of ethanol, the diluent, was 0.1% (v/v).
The sampling and data analysis involved the use of pClamp 8.1
software (Axon Instruments). Experiments were carried out at
room temperature (25uC).
Isolation of rat primary VSMCs. Primary cell cultures of
VSMCs were established with cells removed from abdominal
aortas excised from 4-week-old Wistar rats. Isolation of aortic
VSMCs followed the method of Campbell et al [39]. The cells
were suspended in a growth medium (DMEM supplemented with
10% (v/v) fetal bovine serum [FBS] (JRH Biosciences, Lenexa,
KS, USA), 2.2 g/L NaHCO3, 100 U/mL penicillin G, and
100 mg/mL streptomycin) and seeded into 24-mm glass coverslips
in 6-well plates (for LSCM) or a 0.5-mL chamber (for patch-
clamp). Cells were cultured at 37uC in a humidified atmosphere of
5% CO2 in air. The experimental protocol was approved by the
University Research Committee, and the animal protocol was in
full compliance with the Guidelines for Animal Experimentation
developed by the university.
Determination of intracellular free [Ca
2+]i. [Ca
2+]i was
determined in adherent cells after 60 min of loading with 20 mM
Fluo3-AM in HBSS, as described previously [40]. Fluorometric
data were obtained by means of LSCM (Zeiss LSM 510 META).
The Fluo-3 dye was excited with a 488-nm wavelength argon laser
beam and the emission fluorescence was monitored at 525 nm.
[Ca
2+]i was calculated according to the method of Grynkiewicz, et
al [41]. At the end of the experiment, Triton X-100 and,
subsequently, EGTA were added at final concentrations of 0.1%
and 1 mM, respectively, to obtain the fluorescence maximum
(Fmax) and the fluorescence minimum (Fmin). [Ca
2+]i was
determined from the equilibrium equation, [Ca
2+]i=K d
(F2Fmin)/(Fmax2F), where F is the experimental value of
fluorescence and K was defined as 0.4 mM. [Ca
2+]i was
measured at base line first. After the cells were treated with 16c
for 10 min, the agonists, KCl and TG, were added and [Ca
2+]i
was determined.
Analysis of statistics. Data were presented as mean 6 S.E.
Group differences were analyzed by Student’s t test. The effect of
16c on currents was evaluated by Student’s paired t-test. P,0.05
was considered statistically significant.
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